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ABSTRACT  
Bio-isosteric replacement is a frequently used tool in medicinal chemistry. Whilst the 
pharmacological activity is not influenced by the exchange of substituents, the solid-state 
characteristics and formation of different crystal forms may well be altered dramatically, 
jeopardising the processability and safety of the drug compound. In this study we investigate 
a series of triphenylimidazole (TPI) derivatives as model compounds with the bio-isosteric 
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exchange of only one halogen position (F, Cl, Br, I). Crystallisation from two industrially 
used solvents (methanol and acetonitrile) reveals solvate formation of all TPIs, for which the 
basic hydrogen bonded motif does not change. The three-dimensional packing depends on the 
size of the substituent and changes from fluoro- to chloro- and bromo-substitution but 
remains the same for the larger iodo-substituent. From acetonitrile, only F-TPI and Cl-TPI 
form an isomorphic channel solvate, which in both cases desolvates reversibly to an 
isomorphic crystal form. Due to the halogen atom lining of the channels, bromine and iodine 
are too large to generate a stable packing. This study illustrates the importance of 
understanding the influence of bio-isosteric substitution on the solid-state, in order to best 
utilize this common tool. 
Introduction 
The development of new pharmaceutical compounds to treat emerging and pandemic 
diseases such as ebola or long-standing problems such as bacterial infections is amongst the 
key topics of pharmaceutical research. It demands a steady stream of novel pharmaceutical 
compounds to tackle the disease in question. One of the tools used in the area of medicinal 
chemistry is bio-isosteric replacement, which is the replacement of substituents of a lead 
molecule with other chemical groups without changing the overall biological activity.
1, 2
 This 
enables the medicinal chemist to improve specific properties, such as solubility, crystallinity, 
metabolic stability etc., which subsequently will improve the overall processability of the 
new drug compound. This concept has been applied to as diverse drug classes as 
cannabinoids
3
 and HIV antivirals.
4
 The selection of replacement groups is nowadays heavily 
helped by in silico studies and property predictions.
5-7
 
Even though this approach has been used for over 60 years,
8
 the implications of bio-
isosteric replacements of substituents, which sometimes differ vastly in size and/or 
electronics, on the crystallisation properties of the new molecule have been widely ignored. 
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Small organic molecules show a high probability of crystallising in multiple crystal forms, 
which may differ in physico-chemical characteristics such as melting point or solubility.
9-12
 
The latter characteristic is especially important for pharmaceuticals, as solubility and 
especially water solubility is directly linked to bioavailability of the drug compound and thus 
its pharmacological activity in patients. In addition to crystal forms that contain the desired 
molecule, solvates incorporate solvent molecules from the crystallisation process.
13
 Solvates 
can be interpreted as intermediates formed during the crystallisation process,
14, 15
 and can 
introduce traces of unwanted solvent into the pharmaceutical product, which can prove 
harmful or toxic to the patient. Thus, the levels of residual solvent in these applications are 
regulated.
16
 On the other hand, solvates represent a route to obtain novel unsolvated crystal 
forms, which are not accessible by direct crystallisation.
17-22
  
The inclusion of solvent molecules into crystal forms has been widely studied, not only in 
the pharmaceutical field. The influence of solvate formation has been studied in a co-crystal 
system that has been crystal-engineered to undergo photodimerisation. It was found that the 
inclusion of acetonitrile leads to a molecular arrangement allowing photodimerisation, whilst 
the methanol solvate hinders this.
23
 In other studies, inclusion has been utilised to separate 
xylenes
24
 showing a clear preference of one guest over another, 
25
 or to store volatile 
guests.
26, 27
 Inclusion complexes have recently become focus of attention to study the 
incorporated molecules, either in an unusual conformation,
28
 or to obtain structural 
information of a hard to crystallise compound.
29, 30
 
Considering the variation in size and interaction potential in bio-isosteric groups, the choice 
of replacement group will influence the crystal structure of the substances, as has recently 
been shown for a series of trityl compounds.
31
 In addition, change of halogen substituents 
from chloro via bromo to iodo on phloroglucinol has been shown to influence the 
incorporation mode of water into the crystal structure.
32
 We are thus systematically 
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investigating the influence that the change of only one substituent has on the crystallisation 
behaviour and polymorphism of model compounds.
33
 In order to reduce the possibility of 
strong interactions between the molecules, we use 2,4,5-triphenylimidazoles (lophine, TPI, 
Figure 1) as our model, which can only donate and accept one hydrogen bond and show thus 
a reduced complexity compared to pharmaceutically used compounds. Lophine derivatives 
are used as core structures in medicinal chemistry,
34
 as well as for photophysical 
applications.
35-37
 
During our work on the polymorphism of halogenated TPIs, we investigated a series of 2-
(4′-p-X-phenyl)-4,5-diphenylimazoles (X-TPI; X = F, Cl, Br, and I). These substituents are 
frequently exchanged for bio-isosteric replacement,
38
 and do not significantly change the 
overall electronics of the resulting compounds. However, the substituents vary considerably 
in size, with F having the smallest van-der-Waals radius with 1.47 Å, Cl with 1.75 Å, Br with 
1.85 Å to I with 1.98 Å. In the present study we report our results of crystallisation 
experiments with two standard solvents, methanol and acetonitrile, which are frequently used 
in pharmaceutical processes. 
 
Figure 1. Molecular structure of 2,4,5-triphenylimidazole (TPI) derivatives (lophines) used 
in this study. 
Experimental section 
Materials 
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Benzil, p-halogenbenzaldehyde (F, Cl, Br, I), ammonium acetate, potassium carbonate and all 
organic solvents were purchased from Sigma Aldrich and used without further purification. 
Methods 
Synthesis 
All TPIs were synthesised using the literature method.
39
 Equimolar amounts of benzil and 
substituted benzaldehyde were suspended in acetic acid with 10-fold amount of ammonium 
acetate. The suspension was then heated in a microwave to 180 °C for 5 min and cooled to 
room temperature. The resulting solution was then poured into ice water and neutralised with 
K2CO3 forming a beige precipitate. This was collected by filtration and washed with H2O 
before recrystallisation. 
Crystallisation methods 
Approximately 10 – 20 mg compound was used in each crystallisation experiment. For slow 
cooling and fast cooling experiments, sufficient solvent was added to produce a hot-saturated 
solution. These were then left to cool to room temperature in an insulating wooden block 
(slow cooling) or quenched in an ice and water bath (fast cooling). For evaporation, the 
material was dissolved in sufficient solvent to produce an undersaturated solution at room 
temperature and let stand to evaporate. Precipitation was conducted by producing a hot 
saturated solution and adding at least double the volume of cold (room temperature) diethyl 
ether as anti-solvent. The crystals forming were immediately removed from solution in case 
of the fast cooling and precipitation experiments, whilst evaporation and slow cooling 
experiments were left for one day before analysis. 
Differential scanning calorimetry 
Differential scanning calorimetry (DSC) was performed with a Q2000 (TA instruments, New 
Castle, DE, USA). Approximately 1 to 3 mg of sample were accurately weighed 
(microbalance, Sartorius, Göttingen, Germany) into sealed Al pans and submitted to a ramp 
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scan in the range from 25 to 370 °C with a heating rate of 10 °C min
-1
. Dry nitrogen was used 
as the purge gas (purge: 50 mL min
-1
). The instrument was calibrated for temperature and 
energy in the respective temperature range with pure indium (purity 99.999%, m.p. 156.6 °C, 
heat of fusion 28.45 J g
-1
). 
Thermogravimetric analysis 
Measurements were performed with a Q500 thermogravimetric system (TA instruments, New 
Castle, DE, USA). Samples of approximately 2 to 6 mg were accurately weighed into 50 μl 
platinum pans and subjected to non-isothermal TGA at a heating rate of 10 °C min
-1
. 
Nitrogen was used as purge gas at a purging rate of 60 ml min
-1
. 
X-ray diffractometry  
Powder X-ray diffraction patterns were recorded using an Empyrean diffractometer 
(Panalytical, Almelo, Netherlands) in Bragg-Brentano geometry with Cu-Kα radiation, 
graphite monochromator, 0.2 mm fixed Soller slits and PIXcel detector. The X-ray tube was 
operated at 40 kV and 40 mA, while the samples were prepared on a low-background silicone 
slide sample holder as dry powder. 
Single crystals of F-TPI and Br-TPI methanol solvates were picked, coated in perfluoro 
polyether oil and mounted on MiTeGen sample holders. These were placed directly into a 
pre-cooled cryostream on a Bruker (Karlsruhe, Germany) D8 Quest diffractometer using Mo-
Kα radiation (0.71073 Å). Single crystals of Cl-TPI acetonitrile solvate were picked, coated 
in perfluoro polyether oil and mounted on MiTeGen sample holders. The diffraction 
experiment was carried out on a Rigaku (Sevenoaks, UK) Saturn 724+ diffractometer at 
Station I19 of the Diamond Light Source synchrotron (undulator, λ = 0.6889 Å, ω-scan, 1.0° 
per frame). The data from a 4-component non-merohedral twin were processed using Bruker 
Apex-II software, deconvoluted using CELL_NOW
40
 and corrected for absorption using 
TWINABS 2012/1.
41
 The structure was solved using Olex.solve
42
 and refined using 
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ShelXL.
43
 All non-hydrogen atoms could be located from Fourier difference maps and were 
refined anisotropically. Hydrogen atoms were calculated as geometrical riding models on the 
heavy atom and refined isotropically. 
Results and discussion 
Methanol solvates 
Crystallisation of all TPI derivatives from methanol yielded a crystal form containing solvent 
from crystallisation. The analysis of the respective TG thermograms (Figure 2a) reveals a 
weight loss corresponding to 1 mol methanol per mol TPI (Table 1) for all crystal forms. The 
weight loss of F-TPI starts almost immediately with a slow zero-order loss of solvent, which 
is most likely the evaporation of trapped and surface-bound solvent. The weight loss speeds 
up at temperatures above 60 °C resulting in a one-step solvent release. The solvates of Cl-, 
Br- and I-TPI show slightly higher stability with the start of the weight loss not below 70 °C. 
Cl-TPI shows a single mass loss step comparable to F-TPI, whilst Br-TPI and I-TPI show 
multiple steps. All desolvation events are in the same temperature range as the boiling point 
of methanol, which indicates the high stability of these crystal forms. 
The corresponding DSC thermograms (Figure 2b) show the desolvation as endothermic 
events in temperatures regions comparable to those detected by TG. Interestingly, Br-TPI and 
I-TPI show double peaks, which might be due to partial desolvation followed by melting of 
the remaining intact solvated crystal form, i.e. passing of the peritectic. This observation fits 
well with the two-step desolvation detected by TG. All TPI solvates desolvate into a stable 
crystalline form, which melts at temperatures above 250 °C. 
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Figure 2. Thermoanalytical data of the four TPI methanol solvates: a) TG thermograms and 
b) DSC thermograms. 
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Table 1. Weight loss of the methanol solvates as determined by TG analysis 
 Weight loss weight loss molar calc. weight loss melting unsolvated  
 range [°C] [%] ratio monomolar [%] form (onset) [°C] 
F-TPI 52 - 92 9.31 1.007 9.250 252.9 
Cl-TPI 70 - 102 8.42 0.949 8.831 262.7 
Br-TPI 70 - 118 8.32 1.063 7.867 261.2 
I-TPI 73 - 100 6.80 0.962 7.053 268.0 
The methanol solvates of F-TPI and Br-TPI could be crystallised in sufficient quality to 
obtain single crystal structures. The crystallographic data of these two crystal forms are listed 
in Table 2. Whilst the most common packing motif of imidazole derivatives is the hydrogen 
bonded chain,
35, 44
 this motif is broken in the case of the methanol solvates. In both crystal 
forms, the methanol molecule intercalates into the chains accepting one hydrogen bond from 
one imidazole and donates a second to the next imidazole (Figure 3a). The TPI molecules are 
oriented counter-parallel whilst the chains show a zig-zag ribbon like conformation with the 
edge being formed by the methanol molecules (Figure 3b). These then stack on top of each 
other. The next stacks are connected through weaker C-H∙∙∙π interactions of adjacent non-
substituted phenyl rings. Even though the bromine substituents are closer than twice their van 
der Waals radius (distance: 3.5472(5) Å with 2 x vdW radius: 3.7 Å), the orientation of the 
TPI molecules and thus the geometry of the Br-Br interaction does not directly point towards 
halogen bonding and thus this interaction is less likely to be a driving force of this packing 
motif.  
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Figure 3. Molecular structure of Br-TPI methanol monosolvate: a) hydrogen bonded chains 
with intercalated methanol and b) stacking of the chains in the crystal structure, hydrogen 
atoms are omitted for clarity. Colour code: carbon (grey), hydrogen (light grey), nitrogen 
(blue), oxygen (red), bromine (brown). 
Interestingly, the packing of the stacks is different for F-TPI compared to Br-TPI. 
Whilst the fluoro-substituent is small enough to allow the phenyl rings to properly 
interlock giving a dense packing, the bromine atom is too large for this motif. This 
results in two distinct changes of the packing: firstly, adjacent layers in the 
crystallographic a-direction of Br-TPI move further apart and secondly, the layers shift 
in the crystallographic b-direction of Br-TPI so that the bromine atoms orient along 
channels. This results in a higher symmetry of the crystal structure as well as a slightly 
different long range packing. Whilst F-TPI methanol solvate crystallises in identical 
layers, i.e. AAAA, Br-TPI methanol solvate shows alternating layers, i.e. ABAB, as 
can be seen by the shift in opposite directions of the Br-Br pairs (Figure 4). This 
correlation is reminiscent of polytypism, even though these two crystal forms change 
in their chemical entities (F vs. Br substitution) and thus the term ca, strictly speaking 
not be used.
45
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The crystallographic symmetry of the F-TPI methanol solvate generates disorder in 
the hydrogen bonded chains. The asymmetric unit contains three methanol molecules, 
of which two lie on special positions on the 2-fold axis. Thus, their OH-groups show 
disorder over two positions generating disorder in the position of the proton of the 
imidazole ring. Even though the third methanol molecule can be refined without 
disorder due to its general position, the hydrogen bonded chain forces its OH-group to 
be disordered as well. Since refinement of the structure in P1 resolves the disorder, it 
can be assumed that the crystallographic symmetry would be broken if hydrogen atom 
positions could be located accurately, e.g. by using neutron diffraction. 
 
Figure 4. Molecular packing in the methanol solvates of F-TPI vs. Br-TPI. 
Table 2. Crystallographic data of the methanol solvates of F-TPI and Br-TPI as well as the 
acetonitrile solvate of Cl-TPI as determined by X-ray single crystal diffraction. 
Crystal form F-TPI x MeOH Br-TPI x MeOH Cl-TPI x AcN 
Formula C21H15N2F x CH4O C21H15N2Br x CH4O C21H15N2Cl 
    x 0.25 C2H3N 
Mr (g mol
-1
) 346.39 407.31 341.06 
Crystal system monoclinic monoclinic monoclinic 
Spacegroup P2 P21/c Pn 
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T (K) 120 120 100 
a (Å) 13.164(1) 5.9477(3) 8.854(1) 
b (Å) 5.9105(6) 11.6799(7) 19.875(3) 
c (Å) 23.800(2) 27.003(2) 19.924(3) 
α 90 90 90 
β 104.421(3) 91.541(2) 93.712(2) 
γ 90 90 90 
V (Å
3
) 1793.4(3) 1875.2(2) 3498.6(9) 
Z 4 4 8 
Density (calc, g cm
-3
) 1.283 1.443 1.295 
Abs coeff. (mm
-1
) 0.087 2.205 0.208 
F(000) 728 831 1420 
Crystal size (mm
3
) 0.237 x 0.231 0.619 x 0.188 0.5 x 0.02  
 x 0.12 x 0.093 x 0.02 
Θ range for 2.066 – 25.999 1.90 – 26.00 0.993 – 24.415 
data collection 
Index ranges -15 ≤ h ≤ 15 -7 ≤ h ≤ 7 -10 ≤ h ≤ 10 
 -7 ≤ k ≤ 7 -14 ≤ k ≤ 14 -23 ≤ k ≤ 23 
 -29 ≤ l ≤ 29 -34 ≤ l ≤34 -23 ≤ l ≤ 23 
Reflections col. 20125 51111 34297 
Independent refl. 7045 3697 34297 
Refinement method full-matrix least-squares on F
2
 
Data/restraints/ 7045/1/477 3697/0/236 34287/2/896 
parameter 
Goodness of fit on F
2 
1.021 1.0312 1.012 
R indices [I>2σI] R1 = 0.0583 R1 = 0.0330 R1 = 0.0444 
 wR2 = 0.1091 wR2 = 0.1127 wR2 = 0.1043 
R indices (all data) R1 = 0.1137 R1 = 0.0427 R1 = 0.0509 
 wR2 = 0.1260 wR2 = 0.1255 wR2 = 0.1068 
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Since only two of the four solvates could be crystallised for single crystal diffraction, it is 
difficult to make definite statements about the packing of the other two crystal forms. It can 
be assumed, however, that the hydrogen-bonded chains persist in all four crystal forms. This 
is corroborated by the very similar desolvation temperatures of all four crystal forms 
indicating that the desolvation process has a comparable activation energy, i.e. the energy 
necessary to break the interactions between the solvent and the host molecules. If the basic 
packing motif would change drastically between the four solvates, a wider variation of 
desolvation temperatures would be anticipated alongside different desolvation kinetics.  
The powder X-ray diffractograms of all four TPI derivatives show certain similarities 
(Figure 5). Whilst Br-TPI and I-TPI can be regarded as isostructural, which can be detected 
as a shift of the peak positions without changing the overall pattern, there is no similarity 
between these two, F-TPI and Cl-TPI. It can thus be assumed that the packing of Br-TPI is 
the most efficient for the compounds with large substituents in this series, whilst the smaller 
ones can pack in different arrangements of the basic hydrogen bonded planes. 
 
Figure 5. Powder X-ray diffractograms of the methanol solvates of the four TPI derivatives. 
Calculated patterns of the single crystal structures in light grey. 
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Upon desolvation, all methanol solvates transform into an unsolvated crystal phase (Figure 
6). All of these show low crystallinity and a comparably high amorphous background, but 
reveal distinctly different peak patterns and intensities proving them to be different crystal 
forms to the solvates. However, it can be observed that the desolvated crystal forms of F-TPI 
and Cl-TPI are isomorphous. This is surprising, as the methanol solvates were not structurally 
related. The Br-TPI and I-TPI desolvated crystal forms, on the other hand, reveal no 
similarity in their desolvated modification unlike their methanol solvates. It can thus be 
assumed that the desolvation and concomitant reorganisation process is significantly 
influenced by the different sizes of the substituent and similar packing arrangements are not 
energetically preferable. 
 
Figure 6. Powder X-ray diffractograms of the crystal forms after desolvation of the methanol 
monosolvates. 
Acetonitrile solvates 
Crystallisation of F-TPI from acetonitrile yielded a crystal form, which TG indicated to be a 
solvate (Figure 7a). The weight loss in the range from 60 to 150 °C of 3.194% corresponds 
well to a stoichiometry of a tetarto-solvate (0.25 mol acetonitrile to 1 mol F-TPI, calculated 
mass loss: 3.162%), whilst the broad desolvation temperature range suggests slow 
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desolvation kinetics. The corresponding differential scanning calorimetry (DSC) trace shows 
a well-matched desolvation endotherm in the same temperature range followed by a melting 
endotherm at 252.3 °C (onset) of the corresponding unsolvated crystal form.  
 
Figure 7. TG and DSC thermograms of acetonitrile solvates of F-TPI and Cl-TPI. 
 
Figure 8. Powder X-ray diffractograms of the crystal forms crystallising from acetonitrile 
Changing the TPI substituent from fluorine to chlorine (vdW radius 1.47 Å to 1.77 Å) 
seems not to prevent the formation this solvate. Powder X-ray diffraction proved that the Cl-
TPI solvate is isostructural to that of F-TPI (Figure 8). The thermal data of the Cl-TPI 
solvate (Figure 7b) shows a lower mass loss of 2.942%, as detected by TGA, which again 
corresponds to a tetarto solvate (calculated weight loss 3.009%). The desolvation is almost 
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undetectable by DSC, which is probably due to the broad range of this event from 50 °C to 
almost 200 °C. The respective heat flow will be so low that it is almost indistinguishable 
from the baseline. However, a small but reproducible endothermic peak can be detected from 
150 to 167 °C, which is most likely connected to the desolvation event. Melting subsequently 
occurs at 262.5 °C. 
The change from chlorine to bromine (1.85 Å van-der-Waals radius) as the substituent 
proves too big a change for the acetonitrile solvate formation, and the resulting crystal form is 
unsolvated (Fig. S1). The X-ray powder pattern confirms the presence of a crystal form that 
is not structurally related to the acetonitrile solvates of F-TPI or Cl-TPI as observable by the 
distinctly different peak positions. The same is true for iodo-substituted TPI, which shows no 
detectable weight loss in the TGA measurements (Figure S2) and has distinctly different peak 
positions in the powder pattern. This I-TPI unsolvated crystal form shows no similarity to any 
of the other crystal forms from acetonitrile described above for the other halogens  
 
Figure 9. Crystal structure of Cl-TPI acetonitrile solvate along the crystallographic a-axis. Hydrogen 
atoms omitted for clarity, atomic displacement ellipsoids drawn at 50%, colour code: carbon (grey), 
nitrogen (blue), chlorine (green). 
Although the investigated solvates of F-TPI and Cl-TPI show a strongly anisotropic crystal 
growth with a needle-shaped habit, we were able to solve the crystal structure of the Cl-TPI 
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solvate on instrument I19 at the Diamond Light Source, Didcot, UK. The crystal form 
crystallises in the monoclinic spacegroup Pn with four molecules of Cl-TPI and one molecule 
of acetonitrile in the asymmetric unit. The Cl-TPI molecules arrange in the well-reported 
infinite chains through hydrogen-bonding along the imidazole rings, which are oriented along 
the crystallographic a-axis and also along the preferred axis of growth (Fig. S3). In between 
four chains of host molecules are channels filled with the solvent, which again is oriented 
along the crystallographic a-axis (Figure 9). These channels are lined alternatingly with a ring 
of chlorine atoms and a layer of phenyl rings interacting with the nitrogen atom of the solvent 
through C-H···N hydrogen bonds, which are generally regarded to be weak. The channels, 
however, are stabilised by Cl···Cl halogen bonds (Fig S4), 3.38-3.63 Å in length and at a 
bond angle of 155-162°.  
The diameter of these pores is approximately 4.93 Å, which is only 1.39 Å more than 
double the van-der-Waals-radius of chlorine. This might explain the desolvation behaviour 
observed by TGA over a wide temperature range. The channels containing the acetonitrile 
have a comparable structure to a string of pearls, in which the pearls represent sufficient void 
space for acetonitrile to diffuse through (i.e. the spaces lined with phenyl rings), whilst the 
string spaces represent the constriction by the chlorine atoms. When looked at statically, the 
solvent molecule would not be able to diffuse through these channels and desolvation would 
be accompanied by destruction of the crystal structure and correlated pseudomorphosis (as 
seen for the methanol solvates) or at least cracking of the crystal in order to release the 
solvent. However, as has recently been shown for a porous organic cage structure, crystalline 
materials are not static and molecules within the structure can move around their position.
46
 
The authors of this study show that certain gasses can induce a higher nominal porosity of the 
material by accessing void space within the structure that is only accessible for very short 
periods of time. 
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Since the F-TPI acetonitrile solvate shows an isostructural powder pattern to Cl-TPI, the 
crystal structure has the same string-of-pearls channels with constriction through the fluorine 
atoms. If we assume that the overall crystal structure does not change and the pore size stays 
approximately the same, the pore diameter would be approximately 2 Å more than the van-
der-Waals radius of the lining fluorine atoms, and thus present a smaller obstacle to the 
diffusion of acetonitrile through the pores. This explains the narrower temperature range of 
the desolvation observed by TGA, whilst the initial stability and higher onset temperature of 
the weight loss can be explained by the energy necessary to overcome the intermolecular 
interactions between the solvent and the host molecules in both cases. 
 
Figure 10. Powder X-ray patterns of acetonitrile solvates and respective desolvates of F-TPI 
and Cl-TPI.  
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Figure 11. Powder X-ray patterns of solvated, desolvated and resolvated acetonitrile solvate 
of F-TPI. 
In order to show the close relationship of the solvate to the respective desolvated crystal 
form of F-TPI and Cl-TPI, both solvates were desolvated by heating up to 190 °C using the 
TGA and following the weight change to ensure complete desolvation. PXRD analysis 
confirmed the presence of a new crystal form (Figure 11), which shows peak shift to higher 
angles and thus smaller d-spacings when compared to the original solvated crystal structure. 
Even though these shifts are comparably large, the overall powder patterns change little. As 
the solvated crystal forms, the desolvated forms of F-TPI and Cl-TPI are isostructural. 
Another indication of the isostructurality of both solvates with their respective desolvates is 
the absence of pseudomorphosis or a moving front indicating single-crystal to single-crystal 
transition during desolvation, as has been proven by thermo-microscopy. Final proof, 
however, would only be possible by indexing the powder pattern and solving the crystal 
structure, which is scope of ongoing work. If the two solvate/desolvate pairs are indeed 
isostructural, this would corroborate our hypothesis of the solvent leaving the crystal 
structure by diffusion along the channels. Neither of the new crystal forms is related to those 
observed for Br-TPI or I-TPI.  
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The unsolvated crystal forms were then stored in a saturated atmosphere of acetonitrile to 
probe the reversibility of the desolvation process (Figures 11 and S5). After seven days of 
storage, the PXRD pattern of the materials showed full resolvation to the acetonitrile 
solvates, whilst storage for a further five days only improves the crystallinity of the sample, 
as observed by the increased sharpness of the peaks. The resolvation upon exposure to 
saturated solvent atmosphere could be explained by at least partial retention of the porous 
structure in the desolvated crystal structure, which contracts in order to fill the voids and thus 
minimises the crystal lattice energy. This would facilitate the re-uptake of solvent without the 
necessity of a phase change. Such behaviour has been shown for pharmaceutical hydrates,
47, 
48
 and can pose problems during manufacturing. In this case, the formation of an isostructural 
desolvate poses a way to generate a new anhydrous crystal form.
17, 49
  
Desolvation did not occur when the solvates were stored for 7 days under dry conditions 
(phosphorous pentoxide) at ambient temperature, which shows that a certain amount of 
activation energy is necessary to start the desolvation. However, storing the solvate at 
ambient conditions, i.e. at approximately 50% relative humidity at 23 °C, led to a transition to 
the desolvate over a period of two weeks. It is thus likely that water plays an important role in 
the desolvation of these solvates, and this is the focus of on-going studies. 
Unsolvated crystal forms 
Each of the TPI derivatives shows two unsolvated crystal forms, either from desolvation of 
the solvates or, in the case of Br-TPI and I-TPI, by direct crystallisation from acetonitrile (Fig 
S6). The F-TPI and Cl-TPI desolvates from both solvates are the same modification. This is 
surprising, as it has been shown above that the acetonitrile solvate and its desolvate are 
related or even isostructural. It can be assumed that in this case, the desolvate is so stable that 
it forms during the pseudomorphosis and connected reorganisation of the crystal lattice upon 
release of methanol from the methanol solvate. In the case of Br-TPI, the desolvate of the 
 21 
methanol solvate results in a different crystal form than direct crystallisation from 
acetonitrile. This shows the significance of using solvate formation during crystal form 
discovery, as has been frequently shown for organic compounds.
17, 20, 47, 49
 I-TPI results in the 
same crystal form independent from the solvent/solvate, which again points towards one 
energetically favoured modification.  
Even though this study shows clearly the influence the simple exchange of one substituent 
has on the crystallization characteristics of the resulting compounds, the data presented here 
are only the early stage of the investigation and more information is needed to draw definite 
conclusions of the substituent influence on the solid-state behaviour. What is blatantly clear is 
that the simple exchange of a halogen substituent on a simple model compound with reduced 
complexity can significantly influence the solid-state landscape and the crystal forms 
available. Whilst the change from fluorine to chlorine seems to have less of an effect, 
exchanging chlorine with bromine effects a more radical change in the solid-state behaviour. 
The iodo-substituent then follows the behavior of bromine. 
Conclusion 
In conclusion, we have reported the solvate formation of a series of bio-isosterically 
substituted triphenylimidazoles (2-(4′-p-X-phenyl)-4,5-diphenylimazoles, X-TPI; X = F, Cl, 
Br, and I) in two industrially used solvents, methanol and acetonitrile. There is a clear 
difference of solvate formation depending on the size of the substituent as well as the 
incorporation motif of the solvent. Methanol intercalates into the characteristic hydrogen-
bonded imidazole chains, a motif that most likely persists independently from the substituent. 
However, whilst the packing in two dimensions stays the same, the substituent’s size has an 
influence on the packing in the third dimension. Solvate formation from acetonitrile can only 
be observed for the smaller halogen substituents (F-TPI and Cl-TPI), which form a channel 
solvate that can be desolvated and resolvated, apparently without changing the overall crystal 
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structure. Since the channels are lined with the halogen substituent, bromine and iodine 
substitution proves to be too much of a steric hindrance for the packing to be stable, and thus 
Br-TPI and I-TPI crystallise in non-solvated crystal forms. Two different unsolvated crystal 
forms can be obtained for Br-TPI by desolvation of the solvates or direct crystallisation from 
acetonitrile, whilst F-TPI, Cl-TPI and I-TPI crystallise in the same unsolvated crystal form. 
Overall, there seems to be related behavior between fluoro- and chloro-substitution as well as 
bromo-and iodo-substitution with little correlation between chloro- and bromo-substitution. 
This is an interesting finding and should be verified with additional data. 
Investigation of this series of model compound for bio-isosteric replacement with reduced 
complexity shows the significant influence of the size of the substituent on the crystallisation 
of different modifications. Whilst this can be a big advantage to engineer the appropriate 
crystal form or particle size, e.g. through desolvation and correlated pseudomorphosis, it can 
also pose the problem of residual solvent or unwanted solvate formation and thus increase the 
number of processing steps needed. It is clear from this study that the simple exchange of one 
substituent for its bio-isostere can have massive influence on the solid-state properties of a 
compound and that more research into this field is needed. 
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